Spray-Congealing and Wet-Sieving As Alternative Processes for Engineering of Inhalation Carrier Particles: Comparison of Surface Properties, Blending and In Vitro Performance
Overview
Authors
Affiliations
Purpose: Traditionally, α-lactose monohydrate is the carrier of choice in dry powder inhaler (DPI) formulations. Nonetheless, other sugars, such as D-mannitol, have emerged as potential alternatives. Herein, we explored different particle engineering processes to produce D-mannitol carriers for inhaled delivery.
Methods: Wet-sieving and spray-congealing were employed as innovative techniques to evaluate the impact of engineering on the particle properties of D-mannitol. To that end, the resulting powders were characterized concerning their solid-state, micromeritics and flowability. Afterwards, the engineered carrier particles were blended with inhalable size beclomethasone dipropionate to form low dose (1 wt%) DPI formulations. The in vitro aerosolization performance was evaluated using the NEXThaler®, a reservoir multi-dose device.
Results: Wet-sieving generated D-mannitol particles with a narrow particle size distribution and spray-congealing free-flowing spherical particles. The more uniform pumice particles with deep voids and clefts of wet-sieved D-mannitol (Pearl300_WS) were beneficial to drug aerosolization, only when used in combination with a ternary agent (10 wt% of 'Preblend'). When compared to the starting material, the spray-congealed D-mannitol has shown to be promising in terms of the relative increase of the fine particle fraction of the drug (around 100%), when used without the addition of ternary agents.
Conclusions: The wet-sieving process and the related aerosolization performance are strongly dependent on the topography and structure of the starting material. Spray-congealing, has shown to be a potential process for generating smooth spherical particles of D-mannitol that enhance the in vitro aerosolization performance in binary blends of the carrier with a low drug dose.
Dry Powder Inhalers for Delivery of Synthetic Biomolecules.
Omidian H, Nokhodchi A, Babanejad N Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40005989 PMC: 11858879. DOI: 10.3390/ph18020175.
Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.
Salustio P, Amaral M, Costa P J Aerosol Med Pulm Drug Deliv. 2024; 37(6):307-327.
PMID: 39120712 PMC: 11669763. DOI: 10.1089/jamp.2023.0029.
Development of a Workflow to Engineer Tailored Microparticles Via Inkjet Printing.
Winter C, Zettl M, Mantanus J, Hadjittofis E, Leitinger G, Kolb D Pharm Res. 2022; 40(1):281-294.
PMID: 36380170 DOI: 10.1007/s11095-022-03426-4.